
    
      This study is a randomized, double-blinded placebo-control trial with three parallel groups,
      to make use of a common control group. After being informed about the study expectations and
      potential risks, all individuals providing written informed consent will undergo screening to
      determine eligibility for study entry.

      Participants who meet the eligibility requirements will be randomized in a balanced fashion
      into one of 3 arms:

      Group 1) Zonisamide 100 milligrams (mg) pre-op + Placebo post-op; Group 2) Placebo pre- +
      placebo post-op; and Group 3) Zonisamide 100 mg post-op + placebo post-op
    
  